Bisphosphonates for osteoporosis - Where do we go from here?

New England Journal of Medicine

Volumn 366, Issue 22, 2012, Pages 2048-2051

  Whitaker, Marcea ^a   Guo, Jia ^a   Kehoe, Theresa ^a   Benson, George ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; PLACEBO;

BONE DENSITY; BONE GROWTH; BONE REMODELING; BONE TURNOVER; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CANCER; FEMUR FRACTURE; FRAGILITY FRACTURE; HUMAN; JAW OSTEONECROSIS; LONG TERM CARE; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT DURATION;

EID: 84861705331     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1202619     Document Type: Article

References (5)

1. Food and Drug Administration. Background document for meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee. September 9, 2011 (http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ DrugSafetyandRiskManagementAdvisoryCommittee/UCM270958.pdf).
2. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial. JAMA 2006;296: 2927-38.
3. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012;27:243-54.
4. Mellström DD, Sörensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-8.
5. Schwartz AV, Bauer DC, Cummings SR, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010;25:976-82.